Key Highlights

  • Revenue rose to USD 13.2 million from USD 7.6 million, earned under the GSK collaboration agreement.
  • The net loss was USD 61.9 million, or USD 0.30 per share, compared with USD 53.9 million, or USD 0.32.
  • Research and development expense rose USD 8.0 million to USD 53.8 million, and general expense reached USD 25.4 million.
  • Cash, cash equivalents and marketable securities totaled USD 431.0 million, which management believes funds twelve months of operations.

Quarter Results

Wave Life Sciences (NASDAQ:WVE) filed its quarterly report for the period ended Sept. 30 on Tuesday. The clinical-stage biotechnology company develops RNA medicines on its PRISM platform, which combines RNA interference, RNA editing, antisense silencing and splicing modalities.

Revenue was USD 13.2 million, compared with USD 7.6 million, and comprised revenue under the GSK collaboration agreement. Research and development expense rose USD 8.0 million to USD 53.8 million from USD 45.9 million. External expense rose USD 1.8 million for the INHBE program, including WVE-007, and USD 2.1 million for the alpha-1 antitrypsin deficiency program, WVE-006, while it fell USD 1.3 million for the Duchenne muscular dystrophy program and USD 0.2 million for the Huntington's disease program. Other research and development expense rose about USD 5.7 million, including PNPLA3, additional preclinical programs and compensation.

General and administrative expense rose USD 7.3 million to USD 25.4 million on compensation and external costs. Other income, net was USD 4.1 million versus USD 2.5 million. The net loss was USD 61.9 million, or USD 0.30 per share, versus USD 53.9 million, or USD 0.32.

Nine-Month Results and Liquidity

For the nine months, revenue was USD 53.7 million versus USD 25.5 million. Research and development expense was USD 152.6 million versus USD 130.0 million, and general and administrative expense was USD 72.2 million versus USD 54.4 million. The net loss was USD 157.4 million, or USD 0.78 per share, compared with USD 151.2 million, or USD 0.92.

Net cash used in operating activities was USD 173.3 million versus USD 153.7 million. The company purchased USD 236.5 million of marketable securities. Cash, cash equivalents and marketable securities were USD 431.0 million at Sept. 30, and management believes that is sufficient to fund operations for at least twelve months, while cautioning that it may use capital sooner than it currently anticipates.

Pipeline Priorities

The filing prioritizes three programs using GalNAc delivery for hepatic and metabolic disease. WVE-007 is a GalNAc-conjugated siRNA targeting inhibin βE for obesity, designed to induce fat loss while preserving muscle mass. In preclinical diet-induced obesity mouse models, a single dose produced durable silencing and weight loss similar to 28 days of daily semaglutide injections, supporting once or twice a year dosing in humans, per the filing.

WVE-006 is a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, and WVE-008 is an RNA editing oligonucleotide for PNPLA3 I148M liver disease. The clinical-stage portfolio also includes WVE-N531, an exon 53 splicing oligonucleotide for Duchenne muscular dystrophy, and WVE-003, an allele-selective oligonucleotide for Huntington's disease. The company cites about 175 million people in the United States and Europe, and over one billion globally, living with obesity.

RNA Medicine Markers to Follow

Tracking points include clinical updates for WVE-007, WVE-006 and WVE-008, GSK collaboration revenue relative to USD 13.2 million, and operating cash use against USD 173.3 million for nine months. Further items are research and development spending against USD 53.8 million and cash and marketable securities against USD 431.0 million.